152
Views
17
CrossRef citations to date
0
Altmetric
Review

Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies

, , , &
Pages 1-7 | Published online: 09 Jan 2019

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune, multisystem rheumatic disease with significant impact on health-related quality of life (HRQoL). Patient-reported outcomes (PROs) provide valuable data on patient perceptions across a variety of domains, such as HRQoL, pain, fatigue, and depression. The measurement and results of PROs with respect to HRQoL in randomized controlled trials (RCTs) on belimumab (B-lymphocyte stimulator inhibitor) in SLE are reviewed here, including BLISS-52 and BLISS-76, as well as publications related to belimumab trials that included HRQoL data. Other trials that evaluated belimumab did not include HRQoL data and were therefore not included in the analysis. The BLISS-52 and BLISS-76 RCTs met their primary endpoints and demonstrated improvements in PROs, measured by the 36-item Short Form Health Survey, EuroQol 5 Dimensions, and Functional Assessment of Chronic Illness Therapy-Fatigue Scale. Belimumab was shown overall to improve PROs in adult autoantibody-positive lupus patients.

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune, multisystem rheumatic disease with significant impact on many dimensions of patients’ well-being, causing marked impairment in health-related quality of life (HRQoL).Citation1 Evidence suggests that the impact on HRQoL experienced by SLE patients is not adequately captured by assessments of physician-assessed disease activity and damage alone.Citation2 Patient-reported outcomes (PROs) reflect the patient’s perspectives of their illness, HRQoL, and well-being, and can be helpful in informing treatment decisions.Citation1 Recognizing their value, PROs are identified as an independent core domain by the Outcome Measures in Rheumatology (OMERACT) and other regulatory agencies and health care decision makers. OMERACT recommended four domains to be assessed in SLE randomized controlled trials (RCTs) and longitudinal observational studies: disease activity, HRQoL, damage, and adverse events.Citation3 The US Food and Drug Administration (FDA) requires that control group participants in SLE RCTs receive, at minimum, standard of care therapy.Citation4 Detecting a difference in endpoints between the treatment and control groups may be challenging if a similar level of response to the experimental, add-on treatment is observed. To address this challenge, responder vs non-responder analysis is used to detect differences in outcomes. The metrics and results of PROs in the belimumab RCTs in SLE are reviewed here.

Belimumab in SLE

Similar to the clinical heterogeneity of SLE,Citation5 its etiopathogenesis is also multifactorial, involving environmental (eg, sex hormones, ultraviolet light, viral infections), genetic and epigenetic, hormonal, and immunologic factors.Citation6,Citation7 In genetically predisposed individuals, a normal immune response is impaired, leading to increased autoantibodies and activation of the innate and adaptive immune responses.Citation6,Citation8,Citation9 Patients with SLE have both abnormal activation pathways and activation of a large proportion of B and T cells causing autoimmunity and inflammation.Citation8 B cells play a crucial role in the pathogenesis of SLE, including acting as precursors for plasma cells that secrete autoantibodies, presenting antigenic peptides to T cells, and secreting pro-inflammatory cytokines that amplify and downregulate immune responses.Citation8Citation12 Not surprisingly, given the central role for B cells in the pathogenesis of SLE, B cells emerged as a potential therapeutic target.Citation13 Recent therapeutic interventions focus on strategies such as inhibiting B-cell activation, decreasing B-cell survival, or deleting specific lineages of B cells.Citation10 B-lymphocyte stimulator (BLyS), also known as B-cell activating factor (BAFF), and a proliferation-inducing ligand, are cytokines belonging to the tumor necrosis factor ligand superfamily; they activate B-cell stimulation and maturation of B cells through the binding of several receptors on B cells.Citation14,Citation15 Studies have demonstrated that BLyS levels are correlated with anti-dsDNA antibody levels and SLE disease activity,Citation14Citation16 therefore representing a potentially important therapeutic target in SLE.Citation13 Belimumab (Benlysta) is a human IgG1k monoclonal antibody that binds BLyS/BAFF, thus preventing it from binding to its receptors on B cells. Consequently, belimumab depletes activated and naïve B cells but not directly memory B cells.Citation8,Citation14,Citation17 In 2011, intravenous (IV) belimumab was approved for the treatment of SLE, the first time for a new therapy in >50 years.Citation13 In 2017, the subcutaneous belimumab formulation was approved in the USA, Japan, and the European Union.Citation18,Citation19

RCTs of belimumab in SLE

The efficacy of belimumab in addition to standard of care in adult patients with autoantibody-positive SLE has been demonstrated in four phase III, multicenter, prospective RCTs. ( summarizes the trials.) Inclusion criteria for the four trials were very similar and differences are highlighted in : age ≥18 years, classification of SLE according to the American College of Rheumatology criteria, seropositivity for autoantibodies, and a stable treatment regimen with glucocorticosteroids, antimalarials, or immunosuppressives for at least 30 days before the first study dose. In concordance with OMERACT recommendations and regulatory agencies, the belimumab trials assessed the robustness of responses across four domains: disease activity, damage, adverse effects, and HRQoL.Citation3,Citation20Citation23 The primary outcome measure in all four RCTs was the Systemic Lupus Erythematosus Responder Index-4 (SRI-4) at week 52. The RCTs demonstrated significant improvement in the SRI-4 with 10 mg/kg IV belimumab compared with placebo.Citation20Citation22 Improvements in multiple domains were reported vs placebo and the 10 mg/kg dose received formal approval for treatment of SLE by the US FDA, Health Canada, and European Medicines Agency.Citation25,Citation26 In the pooled data analyses of the BLISS-52 and BLISS-76, responses occurred in 50.6% of patients assigned to belimumab 10 mg/kg vs 38.6% placebo (P<0.001).Citation27 Across the pooled data of the BLISS-52 and BLISS-76 trials, belimumab 10 mg/kg was associated with improvements in multiple domains, including: disease activity, demonstrated by reductions from baseline in Safety of Estrogens in Lupus Erythematosus National Assessment–SLE Disease Activity Index scores at week 52; reductions in the incidence and severity of flares; and decreased glucocorticosteroid doses.Citation28 The BLISS-SC trial demonstrated similar treatment effects to the 10 mg/kg IV doses in BLISS-52 and BLISS-76. Importantly, patients with severe active lupus nephritis or central nervous system lupus were excluded from all four trials. During post-marketing experience, in an open-label extension over a 7-year period (1,746 patient-years), adverse events rates due to belimumab either remained stable or substantially decreased.Citation29

Table 1 Summary of the trials

PROs in the belimumab trials

Across all trials, there was an overall consensus that belimumab was superior to placebo, reducing the burden of disease with a safe medication profile.

Besides physician-centered indices, the BLISS-52 and BLISS-76 trials (but not the Northeast Asia Trial) evaluated PROs relevant to HRQoL in SLE, including the generic Medical Outcomes Study 36-item Short Form Health Survey (SF-36 v2); secondary analyses were also performed using other generic questionnaires: the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) and the EuroQol 5 Dimensions (EQ-5D).Citation30,Citation31 Although measuring multiple aspects of HRQoL, these instruments together capture two of the most frequently reported symptoms in SLE: fatigue and pain.Citation32 More specifically, all three – SF-36, FACIT-F, and EQ-5D – capture fatigue, and SF-36 and EQ-5D capture pain as well. As secondary endpoints, these two trials included mean changes in the SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores (at weeks 24 and 52 for BLISS-52, and weeks 24, 52, and 76 for BLISS-76); FACIT-F, and EQ-5D scores at various time points (weeks 12, 24, 52, and 76) (BLISS-76 only).Citation30 Analyses of PRO data from both the BLISS-52 and BLISS-76 trials were performed according to SRI-4 responders vs non-responders across all doses by SF-36 summary and domain scores, FACIT-F and EQ-5D (at weeks 12, 24, and 52, and, for BLISS-76 data, also at 76 weeks).Citation30 In the BLISS-SC trial, FACIT-F was administered at weeks 4, 8, 12, 24, 36, and 52 and analyzed with the corresponding visits.Citation23 The PROs used to measure HRQoL and fatigue, and their results from the BLISS trials, will be reviewed here.

36-Item Short Form Health Survey

The SF-36 was first developed in 1988 and was followed by the Standard SF-36 Health Survey in 1992, containing 36 questions, and is one of the most widely used and studied generic PRO questionnaires in SLE.Citation33 It measures various domains from the WHO quality of life list of domains.Citation2 The questionnaire is scored from 0 (worse health) to 100 (better health), capturing eight domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health.Citation24 From these domains, the PCS and MCS are calculated.Citation24,Citation34 Since the instrument has been introduced in the late 1980s, its psychometric measurement properties across cultures and languages have been well established and it continues to be one of the most common questionnaires included in clinical research studies and RCTs.Citation1,Citation35Citation38 The reliability (internal consistencyCitation39,Citation40 and test-retest reliabilityCitation39Citation41), validityCitation42Citation46 and responsivenessCitation42,Citation44,Citation45,Citation47 of SF-36 have been extensively studied.

It is important to note that PRO measures, such as the SF-36, are to be interpreted in the context of minimal clinically important differences (MCIDs). MCIDs are an important concept used to determine whether a medical intervention improves outcomes perceived by patients to be clinically meaningful.Citation37,Citation48 A clinical intervention is considered clinically meaningful if that PRO score change at follow-up meets or exceeds the MCID for that instrument in that disease.Citation38 MCIDs for improvement and worsening in SF-36 have been established in SLE, as well as MCIDs for FACIT: ≥2.5 point increases and ≥–0.8 decreases in PCS and MCS scores for improvement and worsening, respectively, ≥5.0 point increases and ≥–2.5 decreases in SF-36 individual domain scores for improvement and worsening, respectively,Citation49,Citation50 and ≥4.0 MCID for FACIT improvement; and were applied to the analyses of SF-36 in the BLISS trials. Mean SF-36 domain scores in patients at baseline and week 52 were compared with age- and gender-matched healthy US subjects.Citation20,Citation21 The well-established MCID definition of improvements of ≥10 points on a 0–100 VAS was used for EQ-5D.

A combined analysis across both RCTs revealed that at week 52 mean improvements in SF-36 PCS scores were greater in SRI-4 responders vs non-responders (4.9 vs 2.6; P<0.001) and exceeded MCID.Citation31 Similarly, at week 52, mean improvements in SF-36 MCS were greater in SRI-4 responders vs non-responders (4.4 vs 1.7; P<0.001), and also exceeded MCID.Citation31 In addition, all SF-36 domain scores showed statistically significant improvements in responders vs non-responders (P<0.001).Citation31

Further post-hoc analysis was performed. At 24 weeks, the first major prespecified endpoint of both BLISS trials demonstrated that mean improvements from baseline in SF-36 PCS did not differ significantly between treatment arms with belimumab 10 mg/kg and placebo (+3.34 vs +3.26) in BLISS-52 and (+3.21 vs +3.35) in BLISS-76.Citation20,Citation21 However, by week 52, significant improvements were reported in BLISS-52 PCS scores (+4.19 vs +2.84; P=0.0247) but not in BLISS-76 (+3.44 vs +2.85).Citation20,Citation21 In BLISS-52, improvements were noted with the 1 mg/kg and 10 mg/kg belimumab doses in the following SF-36 domains at 52 weeks: physical functioning, bodily pain, and role-emotional. With the 1 mg/kg dose, there were improvements in the social functioning and general health domains as well. In BLISS-76, statistically significant improvements were reported with the 1 mg/kg dose in the following domains: role-physical, bodily pain, general health, and vitality at week 52.

Functional Assessment of Chronic Illness Therapy-Fatigue Scale

The FACIT-F is a 13-item fatigue questionnaire that assesses self-reported aspects of physical and mental fatigue and impact on function and daily living.Citation2,Citation51 Items are scored using a four-point Likert scale. The score ranges from 0 to 52 and lower scores represent more fatigue. The FACIT-F was originally developed in 1997Citation52 for the assessment of fatigue in patients with anemia, and validated for use in rheumatic diseases.Citation53 The content validity of the FACIT-F was confirmed by Kosinski et alCitation54 in lupus patients. Other psychometric properties of FACIT-F, reliability,Citation55 validity,Citation30,Citation51,Citation55 and responsivenessCitation31 have been demonstrated in several trials. In the SLE population, the instrument’s ability to detect change over time has been consistently demonstrated.Citation2

Similar to the outcomes of the SF-36 in the BLISS trials, at week 52, SRI-4 responders reported higher mean improvements in FACIT-F scores (5.2) compared to non-responders (3.0), but only values reported by SRI-4 responders exceeded the MCID.Citation31 Both belimumab treatment groups demonstrated significant improvements by week 52 compared to placebo, with greater improvements by week 8 in responders, which were sustained through week 52.Citation31 In post-hoc subgroup analyses of FACIT-F in Hispanic or Latino patients in the BLISS-SC trial, improvements were reported over time in both treatment groups and mean changes from baseline were significantly greater in the belimumab compared with placebo groups at weeks 8, 36, and 52, but not weeks 4, 12, and 24. At week 52, more patients who received belimumab reported improvements that equaled or exceeded the MCID in FACIT-F scores ≥4 compared with placebo (44.4% vs 36.1%; OR 1.42, 95% CI 1.05–1.94; P=0.0245).Citation23

EuroQol 5 Dimensions

The EQ-5D is composed of a six-item questionnaire and a VAS, allowing patients to rate their overall health. The VAS is scored from 0 to 100, reflecting “worst imaginable health” to “best imaginable health”. The EQ-5D VAS score permits an economic evaluation, through the calculation of quality-adjusted life-years. The questionnaire portion is a three-item response scale, reporting results as a summary score from 0 to 1, reflecting “death or health worse than death” to “best imaginable health”.Citation1 The impact on disability is assessed in the following five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.Citation1,Citation2 The reliability and validity of the EQ-5D have been established in the SLE population and it is commonly used in RCTs.Citation2 The EQ-5D was evaluated in the BLISS-52 and BLISS-76 RCTs, with changes in the pain/discomfort domain noted.Citation30

Discussion

In the phase III BLISS RCTs, the primary endpoints were met and a combined analysis of SRI-4 responders vs non responders across all treatment groups demonstrated statistically significant and clinically meaningful improvements in PROs.Citation31 These findings supported the approval of belimumab for treatment of patients with adult autoantibody-positive SLE.

As per OMERACT recommendations, both generic and disease-specific instruments should be used to gauge HRQoL; disease-specific PRO instruments can complement generic ones such as SF-36.Citation56,Citation57 While generic instruments allow comparison to other diseases, disease-specific ones may contribute additional information.Citation57 The ultimate goal with these PROs is to identify areas that could potentially be targeted with therapeutic interventions.Citation57

Generic PRO questionnaires frequently evaluated in SLE include the Medical Outcomes Study SF-36, EQ-5D, and the FACIT-F. Several HRQoL domains of importance to SLE patients, such as appearance, confidence, and body image, are not represented in the generic PRO tools such as SF-36. SLE-specific PRO instruments have been developed to capture these domains. These SLE-specific tools include the LupusQoL, SLE Symptom Checklist (SSC), SLE Quality of Life (SLEQoL), Lupus Quality of Life (L-QoL), Lupus Patient-Reported Outcome tool (LupusPRO), Lupus Impact Tracker (LIT), Simple Measure of Impact of Lupus Erythematosus in Youngsters (SMILEY), and Body Image in Lupus Scale (BILS).Citation1,Citation2

In SLE, pain, fatigue, and physical function are frequently assessed both by generic PROs, such as the SF-36 and EQ-5D, and by the SLE-specific LupusQoL and LupusPRO questionnaires.Citation2 The review by Holloway et al in 2014 showed that the SF-36 v2, the LupusQoL, and the FACIT-F demonstrated content and face validity and overall strong psychometric properties in an SLE population.Citation32 More recently, in 2018, Izadi et al reviewed the literature to assess the responsiveness of different PROs to interventions in RCTs. This review confirmed that SF-36 and LupusQoL have strong evidence for adequate psychometric measurement properties.Citation58 In addition, the LIT and Patient-Reported Outcomes Measurement Information System (PROMIS) showed strong evidence for measurement properties; however, PROMIS responsiveness has not been studied in lupus, nor have LupusPRO or LIT been assessed in RCTs.

LupusQoL is an SLE-specific HRQoL capturing the following eight HRQoL domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationships, and burden to others. The LupusQoL has been validated in multiple language cohorts and countries.Citation2 Despite its use in multiple longitudinal observational studies and two RCTs,Citation2 the LupusQoL was not evaluated in the belimumab trials. Inclusion of SLE-specific PRO measurements in clinical trials, such as the LupusQoL, can potentially represent patients’ perspectives of effects of disease and/or treatment on pertinent HRQoL domains not captured by generic metrics such as SF-36. LupusQoL includes additional pertinent domains to patients with SLE: sleep, body image, and sexual health. Two phase III RCTs, assessing the efficacy of epratuzumab in lupus, have included LupusQoL.Citation59,Citation60

To conclude, PRO outcomes in BLISS trials have been assessed as secondary endpoints in a responder–non-responder analysis, which confirmed that clinical improvements measured by the SRI-4 were associated with significant and clinically meaningful reported improvements in HRQoL and fatigue. Thus, it is very important to include PROs, including generic and disease-specific measures, such as SF-36, LupusQoL, and FACIT-F, as secondary endpoints in trials assessing the efficacy of new drugs in lupus. RCTs in SLE have mainly utilized PROs to assess HRQoL, fatigue, and pain; however, as the field rapidly evolves and more trials develop, other PROs can be included to address cognitive function, anxiety, and depression, among other domains.

Disclosure

Dr Z Touma holds a Young Investigator Salary and Operating Awards provided by the Arthritis Society and the Physicians’ Services Incorporated Foundation. Dr Z Touma’s research is supported by a CRA (CIORA)-Arthritis Society Clinician Investigator Award. The University of Toronto Lupus Clinic is supported the Lupus Foundation of Ontario, the Lou Rocca Family, and the Kaiser’s Family. Dr Z Touma has consulted for GlaxoSmithKline, Merck Serono, Pfizer, and Janssen Pharmaceuticals. Dr V Strand serves as a consultant to Human Genome Sciences, now GSK, as well as Abbvie Amgen Corporation, AstraZeneca, BMS, Boehringer Ingelheim, EMD Serono, Genentech/Roche, Glenmark, Janssen, Kypha, Lilly, Novartis, and UCB. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

References

  • MahieuMYountSRamsey-GoldmanRPatient-reported outcomes in systemic lupus erythematosusRheum Dis Clin North Am201642225326327133488
  • KwanAStrandVToumaZThe role of patient reported outcomes in systemic lupus erythematosusCurr Treat Options Neurol201734308321
  • StrandVGladmanDIsenbergDPetriMSmolenJTugwellPOutcome measures to be used in clinical trials in systemic lupus erythematosusJ Rheumatol19992624904979972993
  • Guidance for Industry: Systemic Lupus Erythematosus – Developing Medical Products for Treatment2010 Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdfAccessed December 12, 2018
  • MoscaMCostenbaderKHJohnsonSRHow do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteriaArthritis Rheumatol Epub2018723
  • ParksCGde Souza Espindola SantosABarbhaiyaMCostenbaderKHUnderstanding the role of environmental factors in the development of systemic lupus erythematosusBest Pract Res Clin Rheumatol201731330632029224673
  • KaulAGordonCCrowMKSystemic lupus erythematosusNat Rev Dis Primers201621603927306639
  • Wahren-HerleniusMDörnerTImmunopathogenic mechanisms of systemic autoimmune diseaseLancet2013382989481983123993191
  • BarturenGAlarcon-RiquelmeMESLE redefined on the basis of molecular pathwaysBest Pract Res Clin Rheumatol201731329130529224672
  • DörnerTLipskyPEBeyond pan-B-cell-directed therapy – new avenues and insights into the pathogenesis of SLENat Rev Rheumatol2016121164565727733759
  • ToumaZGladmanDDCurrent and future therapies for SLE: obstacles and recommendations for the development of novel treatmentsLupus Sci Med201741e00023929344386
  • Al RayesHToumaZProfile of epratuzumab and its potential in the treatment of systemic lupus erythematosusDrug Des Devel Ther2014823032310
  • BlairHADugganSTBelimumab: a review in systemic lupus erythematosusDrugs201878335536629396833
  • CrowMKNiewoldTBKirouKACytokines and interferons in lupusWallaceDJHahnBHDubois’ Lupus Erythematosus and Related Syndromes8th edPhiladelphia, PAElsevier/Saunders20136275
  • StohlWMetyasSTanSMB lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observationsArthritis Rheum200348123475348614673998
  • StohlWInhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)Expert Rev Clin Immunol201713662363328164726
  • JacobiAMHuangWWangTEffect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging studyArthritis Rheum201062120121020039404
  • GSK receives European marketing authorisation for self-injectable formulation of Benlysta for the treatment of systemic lupus erythematosus Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-marketing-authorisation-for-self-injectable-formulation-of-benlysta-for-the-treatment-of-systemic-lupus-erythematosus/Accessed December 20, 2018
  • ElaloufOKeelingSOToumaZSubcutaneous belimumab in the treatment of systemic lupus erythematosusImmunotherapy201810131163117330105936
  • NavarraSVGuzmánRMGallacherAEBLISS-52 Study GroupEfficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialLancet2011377976772173121296403
  • FurieRPetriMZamaniOBLISS-76 Study GroupA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis Rheum201163123918393022127708
  • ZhangFBaeSCBassDA pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South KoreaAnn Rheum Dis201877335536329295825
  • StohlWSchwartingAOkadaMEfficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled studyArthrits Rheumatol201769510161027
  • WangCMayoNEFortinPRThe relationship between health related quality of life and disease activity and damage in systemic lupus erythematosusJ Rheumatol200128352553211296953
  • ToumaZSayaniAPineauCABelimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the observe Canada StudyRheumatol Int201737686587328280970
  • CollinsCEDall’EraMKanHResponse to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the observe study in the USALupus Sci Med201631e00011826835146
  • KimSSKirouKAErkanDBelimumab in systemic lupus erythematosus: an update for cliniciansTherap Adv Chron Dis2012311123
  • van VollenhovenRFPetriMACerveraRBelimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of responseAnn Rheum Dis20127181343134922337213
  • GinzlerEMWallaceDJMerrillJTLBSL02/99 Study GroupDisease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusJ Rheumatol201441230030924187095
  • StrandVLevyRACerveraRBLISS-52 and -76 Study GroupsImprovements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trialsAnn Rheum Dis201473583884423524886
  • FurieRPetriMAStrandVGladmanDDZhongZJFreimuthWWBLISS-52 and BLISS-76 Study GroupsClinical, laboratory and health-related quality of life correlates of Systemic lupus erythematosus responder index response: a post hoc analysis of the phase 3 belimumab trialsLupus Sci Med201411e00003125396065
  • HollowayLHumphreyLHeronLPatient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performanceHealth Qual Life Outcomes20141211625048687
  • WareJESherbourneCDThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionMed Care19923064734831593914
  • KianiANStrandVFangHJaranillaJPetriMPredictors of self-reported health-related quality of life in systemic lupus erythematosusRheumatology (Oxford)20135291651165723681396
  • MokCCHoLYCheungMYYuKLToCHEffect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective studyScand J Rheumatol200938212112718991189
  • UrowitzMGladmanDDIbanezDChanges in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosusArthritis Care Res (Hoboken)20146691374137924497416
  • RaiSKYazdanyJFortinPRAvina-ZubietaJAApproaches for estimating minimal clinically important differences in systemic lupus erythematosusArthritis Res Ther20151714326036334
  • AnnapureddyNDevilliersHJollyMPatient-reported outcomes in lupus clinical trials with biologicsLupus201625101111112127497256
  • ThumbooJFengPHBoeyMLSohCHThioSFongKYValidation of the Chinese SF-36 for quality of life assessment in patients with systemic lupus erythematosusLupus20009970871211199927
  • ThumbooJFongKYNgTPLeongKHFengPHThioSTBoeyMLValidation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in SingaporeJ Rheumatol1999261971029918248
  • BabaSKatsumataYOkamotoYKawaguchiYHanaokaMKawasumiHYamanakaHReliability of the SF-36 in Japanese patients with systemic lupus erythematosus and its associations with disease activity and damage: a two-consecutive year prospective studyLupus201827340741628795653
  • NantesSGStrandVSuJToumaZComparison of the sensitivity to change of the 36-item short form health survey and the lupus quality of life measure using various definitions of minimum clinically important differences in patients with active systemic lupus erythematosusArthritis Care Res (Hoboken)201870112513328320078
  • ToumaZGladmanDDIbañezDUrowitzMBIs there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?J Rheumatol20113891898190521724700
  • Yilmaz-OnerSOnerCDogukanFMHealth-related quality of life assessed by LupusQoL questionnaire and SF-36 in Turkish patients with systemic lupus erythematosusClin Rheumatol201635361762225846834
  • McElhoneKAbbottJSuttonCSensitivity to change and minimal important differences of the LupusQoL in patients with systemic lupus erythematosusArthritis Care Res (Hoboken)201668101505151326816223
  • Garcia-CarrascoMMendoza-PintoCCardielMHHealth related quality of life in Mexican women with systemic lupus erythematosus: a descriptive study using SF-36 and LupusQoL(C)Lupus201221111219122422875651
  • DevilliersHAmouraZBesancenotJFResponsiveness of the 36-item short form health survey and the lupus quality of life questionnaire in SLERheumatology (Oxford)201554594094925361539
  • EngelLBeatonDEToumaZMinimal clinically important difference: a review of outcome measure score interpretationRheum Dis Clin North Am201844217718829622290
  • StrandVCrawfordBImprovement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodiesExpert Rev Pharmacoecon Outcomes Res20055331732619807601
  • StrandVAranowCCardielMHLJP 394 Investigator ConsortiumImprovement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placeboLupus200312967768614514130
  • GoligherECPouchotJBrantRMinimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosusJ Rheumatol200835463564218322987
  • CellaDManual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement SystemEvanston, ILCenter on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University1997
  • YellenSBCellaDFWebsterKBlendowskiCKaplanEMeasuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement systemJ Pain Symptom Manage199713263749095563
  • KosinskiMGajriaKFernandesAWCellaDQualitative validation of the FACIT-fatigue scale in systemic lupus erythematosusLupus201322542243023423250
  • LaiJSBeaumontJLOgaleSBrunettaPCellaDValidation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trialJ Rheumatol201138467267921239746
  • StrandVChuADGeneric versus disease-specific measures of health-related quality of life in systemic lupus erythematosusJ Rheumatol20113891821182321885504
  • ThumbooJStrandVHealth-related quality of life in patients with systemic lupus erythematosus: an updateAnn Acad Med Singapore200736211512217364078
  • IzadiZGandrupJKatzPPYazdanyJPatient-reported outcome measures for use in clinical trials of SLE: a reviewLupus Sci Med201851e00027930167315
  • ClowseMEWallaceDJFurieRAEMBODY Investigator GroupEfficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trialsArthritis Rheumatol201769236237527598855
  • FiechtnerJJMontroyTTreatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trialLupus201423990591224795067